Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 250 of the 263 references it cites were found in a registry or an index; 169 of the 250 sources its claims cite were checked for support.

Senescence and cancer — role and therapeutic opportunities

Open access
Schmitt, Clemens A., Wang, Boshi, Demaria, Marco · 2022 · Nature Reviews Clinical Oncology

Abstract

Cellular senescence is a state of stable, terminal cell cycle arrest associated with various macromolecular changes and a hypersecretory, pro-inflammatory phenotype. Entry of cells into senescence can act as a barrier to tumorigenesis and, thus, could in principle constitute a desired outcome for any anticancer therapy. Paradoxically, studies published in the past decade have demonstrated that, in certain conditions and contexts, malignant and non-malignant cells with lastingly persistent senescence can acquire pro-tumorigenic properties. In this Review, we first discuss the major mechanisms involved in the antitumorigenic functions of senescent cells and then consider the cell-intrinsic and cell-extrinsic factors that participate in their switch towards a tumour-promoting role, providing an overview of major translational and emerging clinical findings. Finally, we comprehensively describe various senolytic and senomorphic therapies and their potential to benefit patients with cancer.

Overview

CoChat Summary

# TL;DR

This is a narrative review arguing that cellular senescence has a dual role in cancer: it can suppress tumor initiation and aid immune clearance, but persistent senescent cells can also promote relapse, metastasis, and treatment toxicity through the SASP. The authors conclude that senolytic and senomorphic strategies are promising, but clinical evidence is still limited and the best therapeutic window and dosing remain unresolved.

# Key findings

  • Senescence is described as a natural barrier to tumorigenesis and is “widely detected in premalignant lesions” from patients with cancer, supporting a tumor-suppressive role.
  • The review states that anticancer therapy induces senescence and that this can contribute to treatment-related adverse events such as fatigue, frailty, cardiac dysfunction, hepatic failure, renal failure, inflammation, bone loss, and muscle weakness.
  • Senescent cells can also promote cancer progression through SASP-mediated effects including chronic inflammation, mitogenic signaling, stemness, angiogenesis, migration and invasion, genotoxicity, and immunosuppression.
  • Therapeutic targeting of senescence is presented as promising: senolytics remove senescent cells, while senomorphics reduce SASP; however, the paper says prospective results of large-cohort oncology trials “remain to be reported.”

# Methods

  • Narrative review / expert synthesis in *Nature Reviews Clinical Oncology* rather than an original experimental study.
  • The authors “researched data for the article” and built the review from published preclinical and clinical studies across cancer biology, therapy-induced senescence, and senotherapeutics.
  • Main analysis is qualitative and mechanistic: the paper compares antitumor versus protumor roles of senescence, then surveys translational and emerging clinical findings on senolytics and senomorphics.

# Limitations

  • The paper explicitly notes that no dependable quantitative assessment can currently separate the long-term contributions of senescence’s beneficial and detrimental effects in patients, and marker-based detection/targeting of senescent subpopulations is not yet feasible in the clinic.
  • It also says that while many candidate senolytics are promising and some have entered clinical trials, “prospective results of large-cohort oncology trials remain to be reported.”
  • Evident from the text: this is a review synthesizing heterogeneous preclinical and correlative human studies, so many conclusions are based on indirect evidence and the paper does not report a new dataset or primary outcome of its own.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41571-022-00668-4

Cites

250 of 250 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

110 Valid · 7 Not valid · 41 Not checked · 50 Own results and interpretations

127 more claims · 68 with their cited sources checked

Create a free account to see all 208 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 65
  • Probably not a substantial claim. 14

Create a free account to see these claims.

Citations

Cites

Show all 263 references

Research works printed but not linked: 1

  1. te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J. & Joel, S. P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62, 1876–1883 (2002).

Cited by

See all 794

Metadata

Authors
Schmitt, C. A., Wang, B., & Demaria, M.
Affiliations
  • Johannes Kepler University of Linz (AT)
  • University Medical Center Groningen (NL)
Corresponding author
Demaria, Marco
Venue
Nature Reviews Clinical Oncology
Published
2022-08-31
Volume
19
Issue
10
Pages
619-636
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W4293747103
Cited by
794
References
263
Citations by year
2026: 130 · 2025: 274 · 2024: 249 · 2023: 105 · 2022: 8
FWCI
27.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
  • PubMed Central (acceptedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
cellular senescence, cancer, carcinogenesis, senescence-associated secretory phenotype, senescence-associated inflammation, senolytic therapy, cell cycle arrest
MeSH terms
Senotherapeutics, Humans, Neoplasms, Cellular Senescence, Cell Cycle Checkpoints, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Senescence and cancer — role and therapeutic opportunities. https://app.cochat.ai/papers/10.1038/s41571-022-00668-4
The paper
Schmitt, C. A., Wang, B., & Demaria, M. (2022). Senescence and cancer — role and therapeutic opportunities. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-022-00668-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.